NCT00489086

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: UCSF Benioff Children's Hospital Oakland · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.

Detailed description

OBJECTIVES: * Determine whether topical tazarotene, administered over a period of 18 months as a chemopreventive agent, reduces the incidence of basal cell carcinomas (BCCs) on treated skin in patients with basal cell nevus syndrome (BCNS). * Expand and refine chemopreventive strategies in patients with BCNS who are at high risk for the development of BCCs. OUTLINE: This is an open-label, multicenter study. Patients apply topical tazarotene cream to the face once daily for 18 months in the absence of unacceptable toxicity.

Conditions

• Neoplastic Syndrome

Interventions

Type	Name	Description
DRUG	tazarotene	Tazarotene is a member of the acetylenic class of retinoids.

Timeline

• Start date: 2004-07-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2007-06-21
• Last updated: 2020-10-29
• Results posted: 2016-02-11

Locations

2 sites across 1 country: United States